Movevit (Mesalazine)

Mesalazine, the active ingredient in Movevit, is a 5‑aminosalicylic acid (5‑ASA) anti‑inflammatory presented as a rectal suppository for rectal use. It is indicated for the treatment of inflammatory bowel disease affecting the colon, such as distal ulcerative colitis and colonic Crohn’s disease. GNH USA supplies Movevit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mesalazine is employed in the management of inflammatory bowel disease, targeting colonic inflammation.

Ulcerative colitis (distal): reduces mucosal inflammation and promotes remission. Crohn's disease (colonic): helps control colonic inflammation and maintain remission. Inflammatory bowel disease: provides local anti‑inflammatory effect to manage disease activity.

Mesalazine may cause a range of adverse reactions, most of which are mild and localized.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal pain or cramping - Nausea or mild vomiting - Headache - Flatulence or bloating - Diarrhea

Serious or Rare Side Effects: - Severe allergic reactions (rash, swelling, anaphylaxis) - Acute severe colitis - Blood dyscrasias (leukopenia, thrombocytopenia) - Pancreatitis - Hepatotoxicity (elevated liver enzymes) - Renal impairment or interstitial nephritis

Before initiating therapy, clinicians should consider several safety measures.

Monitor renal function: assess baseline and periodic kidney tests. Assess for hypersensitivity: discontinue if allergic reactions occur. Avoid in severe hepatic impairment: use with caution or avoid. Pregnancy considerations: safety category unknown; weigh benefits against risks. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Azathioprine or 6‑mercaptopurine: increased risk of bone‑marrow suppression. - Warfarin: may potentiate anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of renal toxicity. - Oral contraceptives: possible reduction in efficacy. - Allopurinol: may increase mesalazine plasma levels. - Trimethoprim‑sulfamethoxazole: potential additive renal effects.